Scinai Immunotherapeutics Ltd.’s Post

Thoughts on this? >> Inmagene to join Nasdaq through reverse merger with Ikena >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #healthcare #productmarketing #pharma #biotech #pharmaceutical

🚀 Exciting news from the pharmaceutical industry! ReviR Therapeutics, based in #Brisbane, has successfully closed a $30 million Series A #financing round, boosting its total #funding to an impressive $54 million. This substantial #investment, primarily from Lapam Capital and supported by existing investors such as CDH Investments and 5Y Capital, underscores the growing confidence in #ReviR’s innovative approach. The company is dedicated to advancing small molecule RNA modulators specifically designed for #neurogenetic diseases, leveraging cutting-edge artificial #intelligence to drive their #researchanddevelopment efforts. The implications of this funding are significant. As #ReviR Therapeutics pushes the boundaries of what’s possible in treating complex #neurogenetic conditions, we can expect to see transformative advancements in #personalizedmedicine and #drug #development. This development not only highlights the potential for AI-driven breakthroughs but also sets a new benchmark for investment and innovation within the industry. Connect, Repost & Follow for more info on the pharmaceutical industry 🌍 #ReviRTherapeutics #AIinPharma #NeurogeneticDiseases #PharmaIndustry #pharmaceutical #pharmaceuticalindustry #healthcare

MSD to Buy B-Cell Depletion #Therapy from Curon Major US drugmaker MSD is to pay up to $1.3 billion to acquire CN201, a novel investigational clinical-stage bispecific antibody for the treatment of B-cell associated diseases, from #biotechnology company Curon Biopharmaceutical. “We continue to identify opportunities to expand and diversify our pipeline,” said Dean Y. Li, MD, PhD, president of MSD Research Laboratories. “Early clinical data have provided robust evidence for the potential of CN201 to target and deplete circulating and tissue B cells with the potential to treat a range of malignant and #autoimmune diseases.” Under the terms of the agreement, MSD said that it will acquire full global rights to CN201 for an upfront payment of $700 million in cash. Curon is also eligible to receive up to $600 million in milestone payments associated with the development and regulatory approval of CN201. Read more on #CMI online: https://lnkd.in/enGsiWsh

#Personalized_Cancer_Medicine Market is estimated to grow at a high CAGR >> https://lnkd.in/dyqrBEKk The #Personalized #Cancer #Medicine Market #research report provides the latest industry data, #growth, key segments and #future #trends on the basis of the detailed #study. This market #report also allows you to identify the future #opportunity and growth rate of the leading #segment based on regions and countries. Abbott, Merck Group, Novartis, Amgen, Celgene, Bayer, Roche, Astellas Pharma, AstraZeneca, Johnson & Johnson, Agilent, Takeda #personalized #cancermedicine #cancertreatment #pharmaceutical #healthcare #medicalscience

💸 On July 8, 2024, Eli Lilly and Company issued a press release alongside Morphic Holdings Inc., announcing Lilly’s plans to acquire Morphic and enhance its inflammatory bowel disease (IBD) portfolio. Morphic is a biopharmaceutical company that develops oral integrin therapies to treat and manage chronic diseases. Among these therapies is a selective oral small molecule α4β7 integrin inhibitor that can be used to manage inflammatory bowel disease. The α4β7 integrin inhibitor, MORF-057, is currently in phase 2 clinical trials for ulcerative colitis and Crohn's disease. 🧬✨ #PharmaNews #EliLilly #Biotech #Acquisition #HealthcareInnovation #MedicalResearch #Biopharma #Investment #MorphicHolding #PharmaceuticalIndustry #BiotechNews

Here at phraktion, we are often asked about how work comes to us and what that work looks like. Our reach is wide and the briefs are extremely varied. So to illustrate how our model works, this series will showcase the projects phraktion is working on. Fibrocor Therapeutics is an early-stage biopharmaceutical company that is growing fast. Part of fuelling this growth is to build investor confidence. "Fibrocor required a TPP for a rare disease indication which needed to be generated asap as part of a potential funding stream. Phraktion's network of experts delivered this in record time and to a very high standard. phraktional consulting works, and worked for Fibrocor." William Newsome, CEO. They needed someone with specific commercial expertise at the right level, ready to work right now. This client approached phraktion through one of the co-founders, already linked to the company.   At phraktion we can solve just about any problem. We now have a network of over 250 experts, which is growing rapidly. The network interacts organically to bring work to it and the network solves the problem. phraktion is a working collective. phraktion is the future of fractional consulting. phraktion.com #pharma #fractional #growth

In the U.S., the largest pharmaceutical market globally, specialty biologics have experienced exponential growth—12.5% on average annually over the last five years—faster than non-biologics, now comprising 46% of spending. The surge is fueled by R&D pipelines and favorable reimbursement policies. Europe is also a key player, with the EMA ensuring the safety and efficacy of these therapies. The future of specialty biologics is exceedingly promising, driven by advancements in biotechnology, personalized medicine, and patient-centric care. By staying at the forefront of innovation and collaboration, companies like Genefic Specialty Pharmacy can capitalize on global specialty biologics market opportunities, transforming healthcare for patients worldwide. Read more: https://loom.ly/_Ozg66o

According to DelveInsight’s analysis, the global next-generation complement therapeutics market is expected to experience significant growth, with a projected CAGR of ~15% by 2030. In 2023, the biologics segment held a substantial revenue share within the next-generation complement therapeutics market. Prominent companies in this field, including Roche, Amgen, CSL, Innovent Biologics, Novartis, Regeneron, Sanofi, Takeda, and UCB, among others, are actively contributing to the market’s expansion. Get detailed insights here: https://lnkd.in/gKDnf-qe #ComplementTherapeutics #Biologics #HealthcareMarket #Pharmaceuticals #MedicalInnovation #MarketAnalysis #PharmaNews #Biotech #ClinicalTrials #DelveInsight #MedicalResearch #HealthcareInnovation #PharmaDevelopment #PharmaNews #marketgrowth #marketforecast #healthcare #healthcareconsulting #marketresearch #healthcare #pharmaceutical #business #blood #blooddisorder #hematology #chemo #cancerresearch #cancer DelveInsight Business Research LLP

Hello connections, Biopharmaceutical companies like Amgen are pioneering breakthroughs in biologics and biosimilars. For example, Amgen's biosimilar drugs are improving access to life-saving treatments for diseases like cancer and rheumatoid arthritis while reducing healthcare costs. 🧫💉 What do you think will be the biggest breakthrough in biopharma in the next five years? Let’s discuss how these advancements are reshaping healthcare. #Biopharmaceuticals #Biologics #HealthcareInnovation

#Update BDL - Beta Drugs Ltd., an oncology-focused pharmaceutical company, has raised INR 117 crore from HealthQuad and other investors. The funding will fuel the company's growth, expand its global presence, and enhance its product portfolio. BDL - Beta Drugs Ltd. aims to become one of the top five oncology companies in India within the next five years. With a strong focus on affordability and accessibility, the company is well-positioned to address the growing demand for oncology treatments in India and emerging markets. Read the story: https://ow.ly/nEHj50UhfQG #Oncology #Pharmaceuticals #HealthcareInvestment #Biotech #PharmaInnovation #CancerTreatment #HealthTech #DrugDevelopment #IndiaHealthcare #StartupFunding